Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study

AIMS/INTRODUCTION: The aim of the present study was to evaluate the safety and efficacy of luseogliflozin added to liraglutide monotherapy in Japanese individuals with type 2 diabetes. MATERIALS AND METHODS: This 52‐week, multicenter, open‐label, single‐arm clinical study enrolled Japanese patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Yutaka, Yabe, Daisuke, Sasaki, Takashi, Fukatsu, Atsushi, Imazeki, Hisae, Ochiai, Hidekazu, Sakai, Soichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835450/
https://www.ncbi.nlm.nih.gov/pubmed/28502112
http://dx.doi.org/10.1111/jdi.12694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835450/
https://www.ncbi.nlm.nih.gov/pubmed/28502112
http://dx.doi.org/10.1111/jdi.12694

Ejemplares similares